跳至主要内容
临床试验/NCT00002275
NCT00002275已完成不适用

Lipid-Based Parenteral Nutritional Support in Patients With the Acquired Immunodeficiency Syndrome and Pneumocystis Carinii Pneumonia. A Comparison of Two Lipid Formulations

Abbott1 个研究点 分布在 1 个国家开始时间: 2001年8月31日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
试验地点
1

研究概览

简要总结

The objectives of this study are:

To establish whether there is a difference in clinical effectiveness of Liposyn II 20 percent as compared with Liposyn III 2 percent in AIDS patients with Pneumocystis carinii pneumonia (PCP). To compare the effects of the two lipid emulsions on immunologic function in AIDS patients. To compare the effect of the two lipid emulsions on HIV load in AIDS patients as measured by reverse transcriptase (RT) in culture. To determine whether a decrease in HIV infectivity is greater in patients given a parenteral feeding regimen containing Liposyn II 20 percent or Liposyn III 2 percent.

研究设计

研究类型
Interventional
主要目的
Treatment

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Concurrent Medication:
  • •All drugs used for the standard treatment of Pneumocystis carinii pneumonia (PCP).
  • •Other drugs for treatment of other AIDS conditions if they have been started more than 3 months prior to study entry.
  • •Patients must have:
  • •Diagnosis of AIDS.
  • •Weight loss > 10 percent of premorbid body weight.
  • •First or second episode of acute Pneumocystis carinii pneumonia (PCP).

排除标准

  • •Co-existing Condition:
  • •Patients with the following conditions or symptoms are excluded:
  • •Do Not Resuscitate (DNR) status.
  • •Biliary stasis.
  • •Patients with the following are excluded:
  • •Do Not Resuscitate (DNR) status.
  • •Biliary stasis.
  • •Prior Medication:
  • •Excluded within 3 months of study entry:
  • •Immunomodulators.
  • •Antiviral new DT

研究者

发起方
Abbott
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验